Is Emgality Approved for Episodic Migraine Prevention?
Yes, Emgality (galcanezumab-gnlm) is FDA-approved for the preventive treatment of migraine in adults, specifically for both episodic migraine (4-14 headache days per month) and chronic migraine (15 or more headache days per month).[1][2]
How Does Emgality Work for Migraine Prevention?
Emgality is a monoclonal antibody that targets and blocks calcitonin gene-related peptide (CGRP), a protein involved in migraine attacks. Administered as a monthly subcutaneous injection (120 mg after an initial 240 mg loading dose), it reduces monthly migraine days by binding to CGRP ligands, preventing pain signaling.[1][3]
Clinical Evidence for Episodic Migraines
Phase 3 trials (EVOLVE-1 and EVOLVE-2) showed Emgality reduced mean monthly migraine days by 4.7-4.8 in patients with episodic migraine (baseline 8.8-8.9 days), compared to 2.7-2.8 days with placebo. About 62-63% of patients had at least a 50% reduction in migraine days.[2][4] Real-world data supports similar efficacy in episodic cases.
Who Can Use It and Dosing Details?
Prescribed for adults with 4+ migraine days monthly. No adjustment needed for episodic vs. chronic. Self-administered via prefilled autoinjector or syringe. Not studied in children or for acute treatment.[1][5]
Common Side Effects and Risks
Most frequent: injection-site reactions (18%), constipation (2%), and hypersensitivity (1%). Rare risks include allergic reactions or worsening migraines initially. Screen for cardiovascular disease, as CGRP affects blood vessels.[1][3]
How Does Emgality Compare to Other CGRP Preventives?
| Drug | Target | Dosing | Episodic Efficacy (Monthly Days Reduced) |
|------|--------|--------|-----------------------------------------|
| Emgality (galcanezumab) | CGRP ligand | Monthly 120 mg | 4.7-4.8[2] |
| Aimovig (erenumab) | CGRP receptor | Monthly/Quarterly | 3.7[6] |
| Ajovy (fremanezumab) | CGRP ligand | Monthly or Quarterly | 5.3[7] |
| Vyepti (eptinezumab) | CGRP ligand | IV every 3 months | 4.0 (Day 1 infusion)[8] |
Emgality matches or exceeds peers in episodic trials but costs ~$700/month (list price; varies with insurance).[5]
Cost, Access, and Patent Timeline
List price: $855 per 120 mg dose. Patient assistance programs available via Lilly. Patent expiry around 2030-2033 per DrugPatentWatch.com, with challenges possible from generics.[9]
Sources
[1]: Emgality Prescribing Information (FDA)
[2]: NEJM: EVOLVE-1/2 Trials
[3]: Lilly Emgality Site
[4]: Stauffer et al., Headache 2018
[5]: GoodRx Pricing
[6]: NEJM: Aimovig Trial
[7]: NEJM: Ajovy Trial
[8]: Lancet: Vyepti PROMISE-2
[9]: DrugPatentWatch: Emgality Patents